CKR 051
Alternative Names: CKR-051Latest Information Update: 30 Jan 2024
At a glance
- Originator CK Regeon
- Class Foot disorder therapies; Skin disorder therapies; Small molecules
- Mechanism of Action CXXC5 protein inhibitors; Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alopecia; Diabetic foot ulcer; Wounds
Most Recent Events
- 08 Jan 2024 CK Regeon completes the phase I safety and pharmacokinetics study in healthy subjects in South Korea (Transdermal) (NCT05833906)
- 25 Apr 2023 Phase-I clinical trials in Alopecia (In volunteers) in South Korea (Transdermal) (NCT05833906)
- 25 Apr 2023 Phase-I clinical trials in Diabetic foot ulcer (In volunteers) in South Korea (Transdermal) (NCT05833906)